Zydus Lifesciences Ltd (ZYDUSLIFE) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Zydus Lifesciences (Formerly known as Cadila Healthcare), a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients and animal healthcare products to wellness products, Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions.

The company provides pathbreaking and life-changing therapies that address unmet medical needs and enhance quality of life by supporting wellness and better health - whether through disease prevention, early detection, or effective management. With a focus on optimizing access and delivery, Zydus aims to revolutionize healthcare for the future. The company continues to unlock new possibilities in lifesciences through novel drug discoveries.

The company is fully committed to and continuously endeavors to achieve environment, health and safety excellence across all the units. The Company continues to invest substantial resources towards sustaining and continuously improving the standards of environment, occupational health and safety as it believes that its responsibility towards the society and the environment extends beyond those laid down by the regulatory authorities. The Company integrates sustainability deeply into its research and development (R&D) strategy, ensuring long-term impact and global health advancement. The Company’s R&D initiatives span across areas such as novel drug discovery, biosimilars, vaccines, specialty products and new dosage form development.

The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. The company is committed to deliver high quality, affordable medicines to the patients by leveraging the best contemporary technology and process improvements.

Business verticals / products

• India Formulations business: The Company’s formulations business in India has been a cornerstone of its overall growth strategy. 
• Consumer Wellness: Zydus Wellness (ZWL), the Company’s subsidiary, spearheads the group’s operations in the consumer wellness space.
• US Formulations business: The Company is one of the leading players in the US generics space, backed by a robust and diverse product portfolio that addresses a wide spectrum of therapeutic needs. The Company’s wholly owned subsidiary Zydus Pharmaceuticals USA Inc. spearheads the Company’s operations in the US.
• International Markets Formulations business: International Markets formulations business will be the third pillar of growth for the Company beside the US and India geographies.

Awards

2008-09:

• The Company received the 'Social and Corporate Governance Awards 2008' in the 'Best Social Responsibility Practice' category presented by the BSE, NASSCOM Foundation and Times Foundation jointly.

2009-10:

• Received the 'IMAI OE Award for the Pioneering and Paradigm Shifting Applications of OE in Tablet Manufacturing' by the KAIZEN Institute.
• Received the 'Best-In-Class Manufacturing Award (Pharma Sector)' by Stars of the Industry Awards.

2010-11:

• Declared the ‘Emerging Company of the Year’ by the Economic Times Awards for Corporate Excellence 2010.

2011-12:

• Zydus Research Centre, Ahmedabad has achieved the full AAALAC accreditation for the fourth year in a row. It has also received accreditation from College of American Pathologists (CAP) upon completion of the inspection process. This accreditation was received in the first inspection itself.

2012-13:

• The Gujarat Ecology Commission selected the Company for good ‘Environment-friendly Practices in Gujarat’. Zydus Research Centre won the Safety Award for the third consecutive year from Gujarat Safety Council.

2013-14:

• Moraiya formulations facility was awarded the 'Gold Award - Pharma Sector, Mega Large Business' by The Economic Times and Frost & Sullivan for achieving operational excellence.

2014-15:

• The Moraiya formulations facility was awarded the 'Green Manufacturing Award - Gold Category' by International Research Institute for Manufacturing.
• The Baddi formulations facility was awarded 'Gold Certificate Merit' in IMEA - India Manufacturing Excellence Awards 2014 by The Economic Times in partnership with Frost & Sullivan.

2015-16:

• It was awarded the Overall India Pharma Excellence Award and the India Pharma Innovation of the Year Award from the Department of Pharmaceuticals, Government of India.

2016-17:

• Topical formulations facility received the ‘Silver Certificate of Merit’ from Frost & Sullivan at India Manufacturing Excellence Awards 2016.

2017-18:

• The manufacturing sites at Moraiya, Baddi and Sikkim received the Silver medal at the National Award for Manufacturing Competitiveness (NAMC) by IRIM global.
• API manufacturing facility at Ankleshwar Ank Unit I bagged a Silver at the Greentech Safety Award 2017 in recognition of its safety systems from the Greentech Foundation, Environment.

2018-19:

• Moraiya formulations manufacturing facility received the Gold Award in the category of Pharma Sector, Large Business at the India Manufacturing Excellence Awards, 2018.

2019-20:

• Cadila Healthcare Limited received CSIR Diamond Jubilee Technology Award for Discovery & Development of Saroglitazar in June 2019.